Bou Farhat, Elias
Mayo Clinic
Brigham and Women's Hospital, Boston, MA 02115, United States.
Citations 2
Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study
Zarif, Talal El, Alaiwi, Sarah Abou, Gariazzo, Eleonora, Santo, Valentina, Garbo, Edoardo , Aldea, Mihaela, Pannu, Sagal, Semaan, Karl , Chehab, Omar , Hoballah, Malak, Y, Gao , Meyers, Daniel, Stukalin, Igor , Li, MT, Jones, Nicholas, Shapira, Ronnie, Vasbinder, Alexi, Hayek, Salim S. , Eid, Marc , Freeman, Dory, Parikh, Kaushal, Desai, Aakash, Cd, Smith, El-Am, Edward, Foderaro, Simone , Baena-, Javier, Cortellini, Alessio, Pinato, David J, Korolewicz, James , Kim, Chul , Sackstein, Paul, Denu, Ryan A, Abdel-wahab, Noha, Neilan, Tomas G. , Lima, Joao A C, Florez, Narjust, Janne, Pasi, Pecci, Federica , Choueiri, Toni K, Kwan, Jennifer M. , Naqash, Abdul Rafeh , Desai, Aakash , El Zarif, Talal , Garbo, Edoardo , Semaan, Karl , Grynberg, Shirly , Bou Farhat, Elias , Eid, Marc , Saad, Eddy , Desai, Aakash P , Kim, Chul , Jänne, Pasi A , Naqash, Abdul Rafeh , Hayek, Salim , Alaiwi, Sarah Abou , Nassar, Amin H. , Gariazzo, Eleonora , Santo, Valentina , Aldea, Mihaela , Paoloni, Francesco , Chehab, Omar , Navani, Vishal , Meyers, Daniel E. , Mittra, Arjun , Grynberg, Shirly , Vasbinder, Alexi L. , Farhat, Elias Bou , Saad, Eddy , Freeman, Dory , El‐Am, Edward , Nana, Frank Aboubakar , Baena, Javier, Herrera, Mercedes, Cortellini, Alessio , Pinato, David J. , Sackstein, Paul , Denu, Ryan , Macaron, Walid , Abdel‐Wahab, Noha , Lima, João A.C. , Florez, Narjust , Jänne, Pasi A. , Ricciuti, Biagio , Choueiri, Toni K.
The Oncologist | July 25, 2026 | Volume: 31 | Issue: 9 | Pages: No page available
Abstract Background There is limited data on immune checkpoint inhibitor (ICI) use in patients with non-small cell lung cancer (NSCLC) and known pericardial effusions. Methods This international multi-center observational retrospective study included patients with advanced NSCLC with or without pericardial effusions receiving ICIs. Immune-related adverse events (irAEs) were graded per CTCAE v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Cox proportional hazards multivariable models assessed the association between survival outcomes and clinicopathologic variables, and an inverse probability of treatment weighting (IPTW) model compared outcomes between the two groups. Results A total of 1248 patients with advanced NSCLC treated with ICIs across 13 institutions were included. Of these, 85 patients (6.8%) had pre-existing pericardial effusions. Compared to controls, patients with pericardial effusions were younger (median age 63 vs 67 years, P = .007), diagnosed more frequently with PD-L1 positive tumors (96% vs 76%, P < .001), and had a higher median number of baseline metastatic sites (3 vs 1, P < .001). IrAEs were similar between both groups (42% vs 38%), and no cardiac irAEs occurred in patients with pericardial effusions. PFS (median 5.6 vs 4.6 months, P = .3) and OS (median 10.2 vs 14.7 months, P = .50) were not statistically different between patients with pericardial effusions and the controls, respectively. In both multivariable and IPTW models, pericardial effusions were not associated with PFS or OS. Conclusions Among patients with NSCLC and pre-existing pericardial effusions, ICIs demonstrate meaningful clinical benefit similar to those without effusions, with no new cardiac or severe toxicities.
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
Chiang, Anne C. , Nassar, Amin H. , Kim, Chul , Farhat, Elias Bou , Matteson, Kelsey, Lau, Shun‐Fat , Gallegos, Jesús Antonio Ocejo , Ardeshir‐Larijani, Fatemeh , Leal, Ticiana, Alam, Sumaye, Gray, Jhanelle E. , Hicks, J. Kevin , Kaldas, David , Baena, Javier, Berjaga, María Zurera, Grohé, Christian , Leuders, Heike, Mingo, Emanuele Claudio , Pancirer, Danny, Cheung, Justin M., Lin, Jessica, Watson, Alexander, Camidge, D. Ross , Parikh, Kaushal , Aggarwal, Vanya , Ahmed, Murtaza, Zhang, Jun , Nagasaka, Misako , Awosika, Nichola, Alhamad, Khaled, Zaman, Unaiza, Gupta, Divya , Lau, Chelsea, Khan, Hina, Liauw, Justin , Brown, Tyiesha , Mosteiro, Miguel , Lopes, Gilberto , Patrick, C. , Young, Lauren K. , Aljumaily, Raid, Mirza, Haris , TAKEBE, Y., Baena, Javier , Nassar, Amin H. , Ocejo Gallegos, Jesus Antonio , Bou Farhat, Elias , Espinar, Javier Baena , Adeyelu, Tolulope Tosin , Abushukair, Hassan , Rakaee, Mehrdad , Takabe, Yamato J. , Ramalingam, Suresh S. , Alam, Sumaiya, Nana, Frank Aboubakar , Citarella, Fabrizio , Cortellini, Alessio , Das, Millie , Ellis-Caleo, Timothy John , Linehan, William Marston , Sridhar, Arthi , Crowley, Fionnuala , Marron, Thomas , Sankar, K. Nathan , Kawtharany, Hassan , Owen, Dwight H , Li, Mingjia , Pinato, David J. , Puri, Sonam , Velázquez, Ana I. , Moliner, Laura , Rocha, Pedro , Evans, Mark G. , Vanderwalde, Ari M. , Elliott, Andrew , Nieva, Jorgé , Patrick, C. , Borghaei, Hossein , Lee, Matthew , Kwiatkowski, David J. , Herbst, Roy S. , Flavell, Richard A. , Naqash, Abdul Rafeh
No container title available | May 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observed comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. Genomic analysis identified distinct NSCLC-like (KEAP1, KRAS, STK11 mutations) and SCLC-like (RB1, TP53 mutations) LCNEC subtypes, with 80% aligning with SCLC transcriptional profiles. Serial sampling revealed stable mutational but shifting transcriptomic landscapes over time. NSCLC-like LCNECs showed elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression, while SCLC-like subtypes expressed higher levels of DLL3. Immunofluorescence confirmed FGL-1 in NSCLC-like LCNECs, and H&E slide analyses indicated fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers. These findings highlight LCNEC’s distinct immunogenomic profile, supporting future investigations into LAG-3, SPINK1, and DLL3-targeted therapies.